Shareholder information Dividends per ADS Share price The table below sets out the dividends per ADS paid in US dollars in 2005 2004 2003 the last five years, translated into US dollars at applicable exchange rates.
At 1st January 12.22 12.80 11.92 Year US$ High during the year 15.44 12.99 13.90 2005 1.57 Low during the year 11.75 10.42 10.00 2004 1.53 At 31st December 14.69 12.22 12.80 2003 1.39 Increase Decrease 20% 5 % 7% 2002 1.24 The table above sets out the middle market closing prices derived 2001 1.11 from the London Stock Exchange Daily Official List.
The companys share price increased by 20% in 2005 from a price of 12.22 at 1st Dividend calendar January 2005 to 14.69 at 31st December 2005.
This compares with Fourth quarter 2005 an increase in the FTSE 100 index of 17% during the year.
Ex-dividend date 15th February 2006 Market capitalisation Record date 17th February 2006 The market capitalisation, based on shares in public issue, of Payable 6th April 2006 GlaxoSmithKline at 31st December 2005 was 85 billion.
At that date GSK was the fourth largest company by market capitalisation on the First quarter 2006 FTSE index.
Ex-dividend date 10th May 2006 Record date 12th May 2006 SmithKline Beecham plc Floating Rate Unsecured Payable 6th July 2006 Loan Stock 1990 2010 The loan stock is not listed on any exchange but holders may require Second quarter 2006 SmithKline Beecham plc to redeem their loan stock at par, i. e. 1 for Ex-dividend date 2nd August 2006 every 1 of loan stock held, on the first business day of March, June, Record date 4th August 2006 September and December.
Holders wishing to redeem all or part of Payable 5th October 2006 their loan stock should complete the notice on the back of their loan stock certificate and return it to the registrar, to arrive at least 30 days Third quarter 2006 before the relevant redemption date.
Ex-dividend date 1st November 2006 Record date 3rd November 2006 Taxation Payable 4th January 2007 General information concerning the UK and US tax effects of share ownership is set out in 'Taxation information for shareholders' on Internet page 186.
Information about the company including details of the share price is available on GSKs website at www.
Dividends Information made available on the website does not constitute part GlaxoSmithKline pays dividends quarterly.
Details of the dividends of this Annual Report.
declared, the amount and the payment dates are given in Note 14.
Investor relations Dividends per share The table below sets out the dividends per share paid in the last five Investor Relations may be contacted as follows: years.
At 24th February 2006, the number of holders of record of shares in the USA was 1,190 with holdings of 1,543,844 shares, and the number of registered holders of the ADRs was 41,589 with holdings of 415,217,646 ADRs.
Certain of these shares and ADRs were held by brokers or other nominees.
As a result the number of holders of record or registered holders in the USA is not representative of the number of beneficial holders or of the residence of beneficial holders.
Control of company As far as is known to the company, it is not directly or indirectly owned or controlled by one or more corporations or by any government.
The company does not know of any arrangements, the operation of which might result in a change in control of the company.
Major shareholders have the same voting rights per share as all other shareholders.
Substantial shareholdings At 24th February 2006, the company had received notification of the following interests of 3% or more in the shares in issue, excluding Treasury shares: BNY Nominees Limited holds 830,443,108 shares representing 14.26%.
These shares are held on behalf of holders of ADRs, which evidence ADSs.
Legal & General Investment Management Limited holds 212,219,375 shares representing 3.64%.
Barclays PLC holds 221,114,143 shares representing 3.80%.
As far as is known to the company, no other person was the owner of 3% or more of the shares in issue, excluding Treasury Shares of the company.
Directors and Officers The interests of the Directors and Officers of the company, as defined in the Companies Act 1985, in share options of the company are given in the Remuneration Report pages 37 to 54.
Exchange controls and other limitations affecting security holders There are currently no UK laws, decrees or regulations restricting the import or export of capital or affecting the remittance of dividends or other payments to holders of the companys shares who are non-residents of the UK.
There are no limitations relating only to non-residents of the UK under English law or the companys Memorandum and Articles of Association on the right to be a holder of, and to vote in respect of, the companys shares.
Documents on display The Memorandum and Articles of Association of the company and other documents referred to in this Annual Report are available for inspection at the Registered Office of the company.
Publications In late March 2006 GSK will publish on the website its Corporate Responsibility Report covering performance in areas including community investment, ethics and integrity, access to medicines, R&D and environment health and safety.
GSK Annual Report 2005 183 INVESTOR INFORMATION Shareholder information continued Nature of trading market Annual General Meeting 2006 The Ordinary Shares of the company were listed on the London Stock The Queen Elizabeth II Conference Centre, 17th May 2006 Exchange on 27th December 2000.
The shares were also listed on the Broad Sanctuary, Westminster, New York Stock Exchange NYSE in the form of American Depositary London SW1P 3EE Shares ADSs from the same date.
The Annual General Meeting is the company's principal forum for The following tables set out, for the periods indicated, the high and communication with private shareholders.
In addition to the formal low middle market closing quotations in pence for the shares on the business there will be a presentation by the Chief Executive Officer on London Stock Exchange, and the high and low last reported sales the performance of the Group and its future development.
There will prices in US dollars for the ADSs on the NYSE.
be opportunity for questions to the Board, and the Chairmen of the Board's committees will take questions on matters relating to those GlaxoSmithKline Pence per share committees.
High Low Investors holding shares in the company through a nominee service Quarter ended 31st March 2006 1500 1424 should arrange with that nominee service to be appointed as a February 2006 1500 1434 corporate representative or proxy in respect of their shareholding in January 2006 1496 1424 order to attend and vote at the meeting.
December 2005 1483 1434 November 2005 1544 1429 ADR holders wishing to attend the meeting must obtain a proxy from October 2005 1473 1395 The Bank of New York which will enable them to attend the meeting September 2005 1442 1343 and vote on the business to be transacted.
ADR holders may instruct Quarter ended 31st December 2005 1544 1395 The Bank of New York as to the way in which the shares represented Quarter ended 30th September 2005 1442 1308 by their ADRs should be voted by completing and returning the voting Quarter ended 30th June 2005 1377 1201 card provided by the bank in accordance with the instructions given.
Quarter ended 31st March 2005 1318 1175 Quarter ended 31st December 2004 1222 1101 Financial reporting Quarter ended 30th September 2004 1209 1042 Financial reporting calendar 2006 Quarter ended 30th June 2004 1201 1067 Announcement of 1st Quarter Results April 2006 Quarter ended 31st March 2004 1299 1060 Year ended 31st December 2003 1390 1000 Announcement of 2nd Quarter Results July 2006 Year ended 31st December 2002 1780 1057 Announcement of 3rd Quarter Results October 2006 Year ended 31st December 2001 2032 1626 Preliminary Announcement of Annual Results February 2007 Publication of Annual Report Review March 2007 US dollars per ADS High Low Results Announcements Quarter ended 31st March 2006 52.77 50.15 Results Announcements are issued to the London Stock Exchange February 2006 52.15 50.31 and are available on its news service.
Shortly afterwards, they are January 2006 52.77 50.15 issued to the media, are made available on the website and sent to December 2005 51.97 50.17 the US Securities and Exchange Commission and the NYSE.
November 2005 53.53 49.16 October 2005 52.39 49.36 Financial reports September 2005 51.28 49.45 The company publishes an Annual Report and, for the investor not Quarter ended 31st December 2005 53.53 49.16 needing the full detail of the Report, an Annual Review.
These are Quarter ended 30th September 2005 51.28 46.47 available from the date of publication on the website.
Quarter ended 30th June 2005 51.40 45.19 The Annual Review is sent to all shareholders on the date of Quarter ended 31st March 2005 50.50 44.48 publication.
Shareholders may also elect to receive the Annual Report Quarter ended 31st December 2004 47.50 41.15 by writing to the companys registrars.
Alternatively shareholders may Quarter ended 30th September 2004 43.84 39.04 elect to receive notification by email of the publication of financial Quarter ended 30th June 2004 43.50 39.44 reports by registering on www.
Quarter ended 31st March 2004 46.93 39.38 Year ended 31st December 2003 47.40 32.75 Copies of previous financial reports are available on the website.
Year ended 31st December 2002 50.87 32.86 Printed copies can be obtained from the registrar in the UK and from Year ended 31st December 2001 57.76 48.80 the Customer Response Center in the USA.
to 24th February 2006 GSK Annual Report 2005 184 INVESTOR INFORMATION Shareholder information continued Ordinary shares The companys shares are listed on the London Stock Exchange.
Registrar The companys registrars are: Lloyds TSB Registrars The Causeway, Worthing, West Sussex BN99 6DA www.
co. uk Tel: 0870 600 3991 inside the UK Tel: 44 0 121 415 7067 outside the UK The registrars also provide the following services: GlaxoSmithKline Investment Plan GlaxoSmithKline Individual Savings Account GlaxoSmithKline Corporate Sponsored Nominee Shareview service Shareview dealing service Share dealing service Hoare Govett operate a postal dealing service in the companys ordinary shares.
It enables investors to buy or sell shares at competitive commission charges.
Further details may be obtained by telephoning 44 0 207 661 6555.
Glaxo Wellcome and SmithKline Beecham corporate PEPs The Share Centre Limited Oxford House, Oxford Road, Aylesbury, Bucks HP21 8SZ Tel: 44 0 1296 414141 The provision of the details above is not intended to be an invitation or inducement to engage in an investment activity.
Advice on share dealing should be obtained from a stockbroker or independent financial adviser.
American Depositary Shares The companys shares are listed on the NYSE in the form of American Depositary Shares and these are evidenced by American Depositary Receipts ADRs, each one of which represents two ordinary shares.
In general, the NYSEs rules permit the company to follow UK corporate governance practices instead of those that apply in the USA, provided that the company explains any significant variations.
This explanation is provided on the companys website.
ADR programme administrator The ADR programme is administered by: The Bank of New York Shareholder Relations PO Box 11258, Church Street Station New York NY 10286-1258 www.
com Tel: 1 877 353 1154 toll free Tel: 1 212 815 3700 outside the USA Customer Response Center Tel: 1 888 825 5249 toll free The administrators also provide Global BuyDIRECT, a direct ADS purchase sale and dividend reinvestment plan for ADR holders.
GSK Annual Report 2005 185 INVESTOR INFORMATION
